Please assess the completion status of the following clinical trial:

Trial Title: Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Before the beginning of the specific protocol procedures must be obtained and documented a written consent form. Patients must have sufficient capacity to understand and sign the consent form.~* Exocrine pancreatic potentially resectable carcinoma, histologically confirmed.~* Aged 18-75 years.~* OMS functional state (FE) from 0-2 and Karnofsky functional state 70%.~* Radiologically or measurable disease, defined as borderline resectability disease.~* Appropriate biological parameters: neutrophils \> 1.500/mL; platelets \> 100.000/mL; hemoglobin \> 10 g/dl.Serum creatinine \< 1,5 x upper limit of normal (LSN); alkaline phosphatase \< 3 x LSN and bilirubin \< 1,5 x LSN; AST and ALT 2,5 x LSN.~* Controlled biliary obstruction in all the patients before their inclusion in the study.~* Absence of peripheral neuropathy grade 2.~* Life expectancy of at least 3 months.~Exclusion Criteria:~* Previous administration of chemotherapy, radiotherapy or any investigational agents for pancreatic cancer treatment.~* Administration of other experimental treatment during this study or in the previous 6 months.~* Pregnancy, inappropriate or unsafe use of contraceptive methods or women who are breast-feeding.~* Clinically significant heart disease(for example: congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not properly controlled with medication or myocardial infarction in the last 12 months).~* Presence of significant ophthalmologic anomaly, included: severe dry eye syndrome, Sjogren syndrome, dry keratoconjunctivitis, severe exposure keratopathy, conditions that might increase the risk of epithelium complications.~* Patients with lack of physical integrity of the upper gastrointestinal tract or bad absorption syndromes or unable to ingest the tablets.~* Other previous bad or concurrent diseases, with the exception of nonmelanoma skin cancer.~* Medical or psychiatric pathologies that are severe or uncontrolled.~* Distant metastases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- QT + QRT (Type: EXPERIMENTAL): Chemotherapy (6 cycles x 14 days): Gemcitabine 1000 mg/m2 (day 1) + Oxaliplatin 100 mg/m2 (day 2) + Tarceva 100 mg/day.~Chemoradiotherapy (5,5 weeks): Gemcitabine 40 mg/m2 (2 days/week) + Tarceva 100 mg/day + Radiotherapy (1,8 Gy/day x 28 doses, total dose: 50,4 Gy).

Based on this trial design, predict the completion outcome and termination type (if applicable).